Is Progyny (PGNY) overvalued or fairly valued?

MarketChacha shows Progyny's valuation in context — a trailing P/E of about 28.2, a forward P/E of about 11.2, a price-to-book of about 4.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Progyny's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (3.31×) from reported figures — education, not a rating.

What is Progyny's revenue?

Progyny reported revenue of $1.3B for FY2025, with net profit of $58.5M, per official filings.

What is the share price of Progyny (PGNY)?

Progyny last traded at $25.94 (-2.5% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Progyny

PGNY · NYSE · Healthcare · United States

Snapshot

TickerPGNY

ExchangeNYSE

SectorHealthcare

IndustryHealthcare Plans

CountryUnited States

Employees835

HeadquartersNew York, United States

Websitewww.progyny.com

Filings tracked15

About Progyny

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Who owns it

Insiders2.0%
Institutions98.0%
Public & other0.0%

439 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.15.12%
FMR, LLC9.13%
Vanguard Portfolio Management LLC6.54%
Vanguard Capital Management LLC4.18%
State Street Corporation3.94%
Ameriprise Financial, Inc.3.60%
Fort Washington Investment Advisors, Inc.3.32%
Geode Capital Management, LLC2.57%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion3.31×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend5.7% → 4.5%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 9% · PAT -3%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $354.9M · EPS 0.53

Est. earnings growth +9.7%

Next fiscal year

Rev $1.5B · EPS 2.32

Est. earnings growth +11.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$1.3B

Net margin

4.5%

ROE

11.3%

Revenue CAGR (2y)

+8.8%

Profit CAGR (2y)

-2.9%

EPS (FY2025)

0.65

Net profit (FY2025)

$58.5M

Ask MarketChacha about PGNY

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.3B	$58.5M	0.65	4.5%	11.3%
FY2024	$1.2B	$54.3M	0.57	4.7%	12.9%
FY2023	$1.1B	$62.0M	0.62	5.7%	11.2%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$350.5M	$28.1M	0.34	8.0%
2026Q1	$328.5M	$24.2M	0.29	7.4%
2025Q4	$318.4M	$12.5M	0.14	3.9%
2025Q3	$313.3M	$13.9M	0.15	4.4%
2025Q2	$332.9M	$17.1M	0.19	5.1%
2025Q1	$324.0M	$15.1M	0.17	4.6%
2024Q4	$298.4M	$10.5M	0.12	3.5%
2024Q3	$286.6M	$10.4M	0.11	3.6%
2024Q2	$304.1M	$16.5M	0.17	5.4%
2024Q1	$278.1M	$16.9M	0.17	6.1%
2023Q4	$269.9M	$13.5M	0.13	5.0%
2023Q3	$280.9M	$15.9M	0.16	5.7%
2023Q2	$279.4M	$15.0M	0.15	5.4%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/7/2026
8-K — Results of operations, Reg FD disclosure
SEC8/6/2026material
8-K — Bylaw/charter change, Shareholder vote results
SEC5/27/2026material
8-K — Other events
SEC5/26/2026material
10-Q filing
SEC5/8/2026
8-K — Results of operations, Reg FD disclosure
SEC5/7/2026material
8-K — Other events
SEC3/13/2026material
10-K filing
SEC2/27/2026
8-K — Results of operations, Reg FD disclosure
SEC2/26/2026material
8-K — Results of operations
SEC1/12/2026material

2025

8-K — Executive/director change
SEC12/17/2025material
10-Q filing
SEC11/7/2025
8-K — Results of operations, Reg FD disclosure
SEC11/6/2025material
10-Q filing
SEC8/8/2025
8-K — Results of operations
SEC8/7/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.